These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Impulse control and related disorders in Parkinson's disease. Weintraub D; Nirenberg MJ Neurodegener Dis; 2013; 11(2):63-71. PubMed ID: 23038208 [TBL] [Abstract][Full Text] [Related]
13. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. Voon V; Schoerling A; Wenzel S; Ekanayake V; Reiff J; Trenkwalder C; Sixel-Döring F BMC Neurol; 2011 Sep; 11():117. PubMed ID: 21955669 [TBL] [Abstract][Full Text] [Related]
14. A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. Chaudhuri KR; Todorova A; Nirenberg MJ; Parry M; Martin A; Martinez-Martin P; Rizos A; Henriksen T; Jost W; Storch A; Ebersbach G; Reichmann H; Odin P; Antonini A Mov Disord Clin Pract; 2015 Jun; 2(2):170-174. PubMed ID: 30713891 [TBL] [Abstract][Full Text] [Related]
15. Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease. Stocchi F; Fossati B; Torti M Expert Opin Drug Saf; 2020 Sep; 19(9):1155-1172. PubMed ID: 32869676 [TBL] [Abstract][Full Text] [Related]
16. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease. Kimber TE; Thompson PD; Kiley MA J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992 [TBL] [Abstract][Full Text] [Related]
17. Dopamine Agonist Withdrawal Syndrome and Suicidality in Parkinson's Disease. Kwan C; Kolivakis T; Huot P Can J Neurol Sci; 2023 Sep; 50(5):779-780. PubMed ID: 35801613 [No Abstract] [Full Text] [Related]
18. Introduction to Parkinson disease (PD) and its complications. Marvanova M Ment Health Clin; 2016 Sep; 6(5):229-235. PubMed ID: 29955475 [TBL] [Abstract][Full Text] [Related]